ePrints

Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria

Lookup NU author(s): Dr Keith Wu, Dr Zarif Jabbar-Lopez

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.

Publication metadata

Author(s): Wu KCP, Jabbar-Lopez ZK

Publication type: Editorial

Publication status: Published

Journal: Journal of Investigative Dermatology

Year: 2015

Volume: 135

Issue: 1

Pages: 13-15

Print publication date: 01/01/2015

ISSN (print): 0022-202X

ISSN (electronic): 1523-1747

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/jid.2014.362

DOI: 10.1038/jid.2014.362

Share